Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Ketamine effects on anxiety and fear-related behaviors: Current literature evidence and new findings

Full text
Author(s):
Silote, Gabriela P. [1, 2, 3] ; de Oliveira, Sabrina F. S. [4] ; Ribeiro, Deidiane E. [2] ; Machado, Mayara S. [4] ; Andreatini, Roberto [5] ; Joca, Samia R. L. [6, 2] ; Beijamini, Vanessa [7, 4, 3]
Total Authors: 7
Affiliation:
[1] Aarhus Univ, Dept Clin Med, TNU, Aarhus - Denmark
[2] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Biomol Sci, Ribeirao Preto, SP - Brazil
[3] Univ Fed Espirito Santo, Biochem & Pharmacol Grad Program, Vitoria, ES - Brazil
[4] Univ Fed Espirito Santo, Hlth Sci Ctr, Dept Pharmaceut Sci, Vitoria, ES - Brazil
[5] Univ Fed Parana, Dept Pharmacol, Curitiba, PR - Brazil
[6] Aarhus Univ, AIAS, Aarhus - Denmark
[7] Univ Fed Espirito Santo, Hlth Sci Ctr, Pharmaceut Sci Grad Program, Vitoria, ES - Brazil
Total Affiliations: 7
Document type: Journal article
Source: PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY; v. 100, JUN 8 2020.
Web of Science Citations: 0
Abstract

Ketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, presents a rapid and sustained antidepressant effect in clinical and preclinical studies. Regarding ketamine effects on anxiety, there is a widespread discordance among pre-clinical studies. To address this issue, the present study reviewed the literature (electronic database MEDLINE) to summarize the profile of ketamine effects in animal tests of anxiety/fear. We found that ketamine anxiety/fear-related effects may depend on the anxiety paradigm, schedule of ketamine administration and tested species. Moreover, there was no report of ketamine effects in animal tests of fear related to panic disorder (PD). Based on that finding, we evaluated if treatment with ketamine and another NMDA antagonist, MK-801, would induce acute and sustained (24 hours later) anxiolytic and/or panicolytic-like effects in animals exposed to the elevated T-maze (ETM). The ETM evaluates, in the same animal, conflict-evoked and fear behaviors, which are related, respectively, to generalized anxiety disorder and PD. Male Wistar rats were systemically treated with racemic ketamine (10, 30 and 80 mg/kg) or MK-801 (0.05 and 0.1 mg/kg) and tested in the ETM in the same day or 24 hours after their administration. Ketamine did not affect the behavioral tasks performed in the ETM acutely or 24 h later. MK-801 impaired inhibitory avoidance in the ETM only at 45 min post-injection, suggesting a rapid but not sustained anxiolytic-like effect. Altogether our results suggest that ketamine might have mixed effects in anxiety tests while it does not affect panic-related behaviors. (AU)

FAPESP's process: 17/26815-1 - Investigation of the involvement of the BDNF-TrkB pathway in the mechanism of action of the rapid and sustained antidepressant-like effect induced by canabidiol
Grantee:Gabriela Pandini Silote
Support type: Scholarships in Brazil - Doctorate
FAPESP's process: 18/12119-6 - Investigation of the molecular mechanisms involved in the rapid and sustained antidepressant-like effects induced by Cannabidiol
Grantee:Gabriela Pandini Silote
Support type: Scholarships abroad - Research Internship - Doctorate